Newborn screening for inherited metabolic disease

Lancet

Volumn 369, Issue 9555, 2007, Pages 5-6

  Grosse, Scott D ^a   Dezateux, Carol ^b  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE;

ACADM GENE; ARTICLE; COGNITION; COGNITIVE DEFECT; COST EFFECTIVENESS ANALYSIS; ENZYME DEFICIENCY; GENE; GENE MUTATION; HUMAN; METABOLIC DISORDER; MORTALITY; NEWBORN; NEWBORN SCREENING; PHYSICAL DISABILITY; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

EID: 33845895264     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60005-1     Document Type: Note

References (14)

1. Wilcken B., Haas M., Joy P., et al. Outcome of neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency in Australia: a cohort study. Lancet 369 (2007) 37-42
2. Wilcken B., Hammond J., and Silink M. Morbidity and mortality in medium chain acyl coenzyme A dehydrogenase deficiency. Arch Dis Child 70 (1994) 410-412
3. Derks T., Reijngoud D., Waterham H., et al. The natural history of medium-chain acyl CoA dehydrogenase deficiency in the Netherlands: clinical presentation and outcome. J Pediatr 148 (2006) 665-670
4. Pollitt R., and Leonard J. Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Arch Dis Child 79 (1998) 116-119
5. Pourfarzam M., Morris A., Appleton M., Craft A., and Bartlett K. Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet 358 (2001) 1063-1064
6. Grosse S., Khoury M., Greene C., et al. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med 8 (2006) 205-212
7. Waisbren S., Albers S., Amato S., et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 290 (2003) 2564-2572
8. Tin W., Fritz S., Wariyar U., and Hey E. Outcome of very preterm birth: children reviewed with ease at 2 years differ from those followed up with difficulty. Arch Dis Child Fetal Neonatal Ed 79 (1998) F83-F87
9. Waddell L., Wiley V., Carpenter K., et al. Medium-chain acyl-CoA dehydrogenase deficiency: genotype-biochemical phenotype correlations. Mol Genet Metab 87 (2006) 32-39
10. Venditti L., Venditti C., Berry G., et al. Newborn screening by tandem mass spectrometry for medium-chain acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis. Pediatrics 112 (2003) 1005-1015
11. Carroll A., and Downs S. Comprehensive cost-utility analysis of newborn screening strategies. Pediatrics 117 (2006) 287-295
12. Pandor A., Eastham J., Beverley C., et al. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess 8 (2004) 1-121
13. Feuchtbaum L., and Cunningham G. Economic evaluation of tandem mass spectrometry screening in California. Pediatrics 117 (2006) 280-286
14. Autti-Ramo I., Makela M., Sintonen H., et al. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland. Acta Paediatr 94 (2005) 1126-1136